

# Vitamin K<sub>2</sub> suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43

Makoto Kaneda<sup>a,b</sup>, Dan Zhang<sup>a,c</sup>, Rajib Bhattacharjee<sup>a,b</sup>,  
Ken-ichi Nakahama<sup>a,\*</sup>, Shigeki Arai<sup>c</sup>, Ikuo Morita<sup>a,b</sup>

<sup>a</sup> *Department of Cellular Physiological Chemistry, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8549, Japan*

<sup>b</sup> *21st Century Center of Excellence Program, Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, Japan*

<sup>c</sup> *Department of Hepato-Biliary Pancreatic Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, Japan*

Received 9 October 2007; received in revised form 6 December 2007; accepted 12 December 2007

## Abstract

The anti-cancer potential of vitamin K<sub>2</sub> (VK<sub>2</sub>) in hepatoma has gained considerable attention but the underlying mechanisms are unclear. Treatment of HuH7 hepatoma cells with VK<sub>2</sub> produced a normal liver phenotype. Following treatment of cells with VK<sub>2</sub>, there was an increase in gap junctional intercellular communication activity, accompanied by up-regulation of connexin 32 (Cx32), dominantly expressed in normal hepatocyte. In contrast, Cx43 expression was inhibited. Moreover, the effect of VK<sub>2</sub> on Cx32 was abolished by over-expression of Cx43. Taken together, we propose that the anti-tumor effect of VK<sub>2</sub> is at least partly due to a decrease in Cx43 promoter activity.

© 2007 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** Vitamin K<sub>2</sub>; Hepatoma; Gap junction; Gap junctional intercellular communication; Connexin 32; Connexin 43

## 1. Introduction

Vitamin K is a family of structurally similar lipophilic 2-methyl-1,4-naphthoquinones, including phyloquinone (K<sub>1</sub>), menaquinones (K<sub>2</sub>), and menadiolone (K<sub>3</sub>). VK<sub>2</sub> is well known as a co-factor of  $\gamma$ -glutamylcarboxylase which converts glutamic acid residues into  $\gamma$ -carboxyglutamyl (Gla) residues of

blood coagulation factors and bone matrix proteins [1,2]. Meta-analysis of randomized controlled trials showed that supplementation with VK<sub>2</sub> reduces bone loss [3]. More recently, many studies suggest that VK<sub>2</sub> has inhibitory effects against hepatic cancer. In a clinical study, VK<sub>2</sub> prevented development of hepatocellular carcinoma (HCC) cells in female patients with liver cirrhosis [4]. *In vitro* studies indicate that the anti-angiogenic activity and anti-proliferation activity of VK<sub>2</sub> might explain the anti-cancer effect of VK<sub>2</sub> [5–7]. However, the precise mechanism by which VK<sub>2</sub> inhibits hepatic cancer is not fully understood.

\* Corresponding author. Tel.: +81 3 5803 5574; fax: +81 3 5803 0212.

E-mail address: [nakacell@tmd.ac.jp](mailto:nakacell@tmd.ac.jp) (K. Nakahama).

Connexin (Cx) is the component protein of the gap junction (GJ) channel, forming structures which mediate intercellular communication. Each GJ is made up of two docked hemichannels (connexons) from neighboring cells, comprising self-assemblies of six Cx proteins [8]. Small molecules (molecular mass of up to 1.5 kDa), ions, second messengers, and metabolites can be directly transferred between neighboring cells through GJs, thereby making possible gap junctional intercellular communication (GJIC) [9,10]. In many tissues, GJIC is responsible for tissue homeostasis such as cardiac conduction and maintenance of CNS function [11,12]. A large number of studies have indicated that Cx genes have a tumor-suppressing effect [13–17]. More than 20 kinds of connexins have been reported and their distributions are tissue specific. Cx32 is dominantly expressed in hepatocytes. Cx32 knockout mice exhibit an increase in the risk of tumorigenesis [18,19]. Cx43 also has tumor-suppressing effects [13,14,16,20,21]; however, it is not expressed in normal hepatocytes and the expression is strongly up-regulated in HCC cells [22,23].

To elucidate the anti-cancer mechanism of VK<sub>2</sub>, we focused on the effects of VK<sub>2</sub> on GJIC activity and Cx gene expression in HCC. The treatment of HuH7 cells with VK<sub>2</sub> inhibited proliferation, and induced a normal liver phenotype. We found that GJIC activity in VK<sub>2</sub>-treated cell was strongly enhanced. We also showed that VK<sub>2</sub> up-regulated Cx32 at the transcriptional level. On the other hand, Cx43 transcription was inhibited by VK<sub>2</sub>-treatment. Finally, we found that Cx43 over-expression abolished the VK<sub>2</sub>-induced expression of Cx32 and albumin. These findings suggest that VK<sub>2</sub> indirectly up-regulates Cx32 expression via reduction of Cx43 promoter activity in HuH7 cells, resulting in an activation of GJIC and induction of normal liver phenotype.

## 2. Materials and methods

### 2.1. Plasmid construction

The cloning of Cx43 cDNA was described previously (pcDNA3.1-Cx43) [20]. The first PCR product containing the human Cx43 promoter sequence from upstream –1546 to +59 was generated by LA *Taq* polymerase (Takara, Shiga, Japan) using the following primers: 5'-GGAAA TAGGATAGCCAACAAGTAAAAGCAA-3' (forward) and 5'-GGAGGATGAAGTAAAATGAAAAGGCAA G-3' (reverse) as the first primers. Human genomic DNA was used as the template. Then, the primers, 5'-AAAGC

TAGCGCCAACAAGTAAAAGCAAAA-3' (forward) and 5'-AAAAGATCTTCCTCACGCCTTCCCCCTAA-3' (reverse) were used as the nested primers to amplify the second PCR product containing the human Cx43 promoter sequence with *NheI* and *BglII* restriction enzyme sites. The PCR products were digested with *NheI* and *BglII* and ligated into a pGL3-basic promoter (Promega, Madison, WI) using Ligation High (Toyobo, Osaka, Japan). The cloning of the human Cx32 promoter was previously described [24].

### 2.2. Cell culture and transient transfection

HuH7, human hepatoma cells (RIKEN cell bank, Ibaraki, Japan) were cultured at 37 °C in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. For transfection,  $2 \times 10^5$  cells were plated on 24-well plates. After 48 h, the cells were transfected with 1 µg of pcDNA3.1-Cx43 or the empty vector using LipofectAMINE 2000 reagent (Invitrogen) according to the manufacturer's instructions. Transfection efficiency was established by real time-PCR using Ex *Taq* polymerase (Takara) and the following primers: 5'-GGATCGCGTGAAGGGAAGAAGC-3' (forward) and 5'-GCTGGAAGGTCGTTGGTC-3' (reverse). These primers can detect transfected rat Cx43, but not endogenous human Cx43 in HuH7 cells.

### 2.3. Cell growth assay

Ten thousand cells were cultured on 24-well plates with or without VK<sub>2</sub> (Sigma, St. Louis, MO) for 72 h. Trypsinized cells in each sample were counted using a Z1 Coulter Particle Counter (Beckman Coulter, Fullerton, CA) after 24 h, 48 h, and 72 h of cultivation.

### 2.4. Quantitative RT-PCR

Total RNA was prepared from HuH7 cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Total RNA (1 µg) was subjected to reverse-transcription using ReverTra Ace (Toyobo) and oligo (dT) primer. The cDNA samples were amplified with Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen). All the analyses were performed by the comparative Ct Method (7500 Fast Real-Time PCR System, Applied Biosystems, Foster City, CA). Cx43-specific primers were as follows: 5'-ACTCAACAGCCTTATTCAT-3' (forward) and 5'-CTATGTATCACCTAATGGA-3' (reverse) for human Cx43 and 5'-GGATCGCGTGAAGGGAAGAAGC-3' and 5'-GCTGGAAGGTCGTTGGTC-3' for rat Cx43. The primers for human  $\alpha$ -fetoprotein were as follow: 5'-TGCCAACTCAGTGAGGACAA-3' (forward) and 5'-TCCAACAGGCCTGAGAAATC-3' (reverse). The other primers for real time PCR were previously described [24].

Download English Version:

<https://daneshyari.com/en/article/2114952>

Download Persian Version:

<https://daneshyari.com/article/2114952>

[Daneshyari.com](https://daneshyari.com)